Compare Merck & Co., Inc. (MRK) vs Vanguard Sht-Term Inflation-Protected Sec Idx ETF (VTIP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Merck & Co., Inc. vs Vanguard Sht-Term Inflation-Protected Sec Idx ETF — how do they compare? Merck & Co., Inc. trades at $130.54 (market cap $323.00B), while Vanguard Sht-Term Inflation-Protected Sec Idx ETF trades at $49.67. The key difference: Merck & Co., Inc. pays a 2.6% dividend while Vanguard Sht-Term Inflation-Protected Sec Idx ETF pays none, and Merck & Co., Inc. is trading nearer its 52-week high, Vanguard Sht-Term Inflation-Protected Sec Idx ETF nearer its low. Which is the better fit depends on your goals.
| MRK | VTIP | |
|---|---|---|
Market Cap | $323.00B | — |
Sector | Health | — |
52-Week High | $131.84 | $50.75 |
52-Week Low | $77.60 | $49.39 |
Enterprise Value | $369.77B | — |
Dividend Yield | 2.6% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MRK trades at $130.90, up 1.81% today, with a bullish technical signal and strong institutional buying interest. The stock shows robust fundamentals with revenue of $65.01B in 2025 and net income of $18.25B, though a high P/E of 104.74 indicates premium valuation. Recent news highlights Merck's acquisition of Terns Pharmaceuticals to bolster its oncology pipeline, reflecting strategic growth initiatives.
Outlook is positive with a consensus price target of $139.90, offering ~7% upside, supported by 67.57% analyst buy ratings. Risks include integration challenges from acquisitions and patent expirations, but strong cash flow and dividend payments provide stability. Investors may find value in Merck's market leadership and pipeline expansion, though valuation metrics warrant caution.
VTIP, the Vanguard Short-Term Inflation-Protected Securities ETF, trades at $49.67, up 0.08% with a bullish technical signal. The ETF focuses on short-term Treasury Inflation-Protected Securities, offering inflation hedging. Recent news highlights institutional buying and inflation concerns, with a dividend declared for July 2026. Technical indicators show mixed signals but overall positive momentum.
Outlook: VTIP provides inflation protection amid rising prices, with potential returns around 3.8% based on current inflation. Risks include interest rate volatility and Fed policy uncertainty. It suits investors seeking low-duration, inflation-linked income, but may underperform if inflation subsides unexpectedly.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →About Vanguard Sht-Term Inflation-Protected Sec Idx ETF
The index is a market-capitalization-weighted index that includes all inflation-protected public obligations issued by the US Treasury with remaining maturities of less than 5 years. The advisor attempts to replicate the target index by investing all, or substantially all, of its assets in the securities that make up the index, holding each security in approximately the same proportion as its weighting in the index.
Read more on VTIP →
